IL127733A0 - Chelating agents and their metal chelates for treating free radical induced conditions - Google Patents

Chelating agents and their metal chelates for treating free radical induced conditions

Info

Publication number
IL127733A0
IL127733A0 IL12773397A IL12773397A IL127733A0 IL 127733 A0 IL127733 A0 IL 127733A0 IL 12773397 A IL12773397 A IL 12773397A IL 12773397 A IL12773397 A IL 12773397A IL 127733 A0 IL127733 A0 IL 127733A0
Authority
IL
Israel
Prior art keywords
chelating agents
metal chelates
free radical
induced conditions
radical induced
Prior art date
Application number
IL12773397A
Other languages
English (en)
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of IL127733A0 publication Critical patent/IL127733A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Semiconductor Lasers (AREA)
IL12773397A 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radical induced conditions IL127733A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (1)

Publication Number Publication Date
IL127733A0 true IL127733A0 (en) 1999-10-28

Family

ID=10795775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12773397A IL127733A0 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radical induced conditions

Country Status (14)

Country Link
US (2) US6258828B1 (OSRAM)
EP (2) EP0936915B1 (OSRAM)
JP (2) JP4162263B2 (OSRAM)
CN (2) CN1228703A (OSRAM)
AT (2) ATE228361T1 (OSRAM)
AU (2) AU720621B2 (OSRAM)
BR (1) BR9709942A (OSRAM)
CA (2) CA2258299A1 (OSRAM)
DE (2) DE69717447T2 (OSRAM)
GB (1) GB9613182D0 (OSRAM)
IL (1) IL127733A0 (OSRAM)
NO (2) NO985917L (OSRAM)
NZ (2) NZ333357A (OSRAM)
WO (2) WO1997049390A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1770299A (en) * 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
KR101312880B1 (ko) 1999-10-01 2013-09-30 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
ES2388064T3 (es) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Formulaciones liposomales de agentes de antraciclina y análogos de citidina
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
BRPI0820832A2 (pt) * 2007-12-14 2015-06-16 Pledpharma Ab Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
CN105688215A (zh) * 2009-07-06 2016-06-22 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
CA2862736C (en) 2012-01-05 2020-09-08 Pledpharma Ab Mixed metal complexes and methods
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014068514A1 (en) 2012-11-02 2014-05-08 Pledpharma Ab Cancer treatment methods
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
MX2016016617A (es) 2014-06-16 2017-03-23 Mayo Foundation Tratamiento de mielomas.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
CA3035653A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
WO1997049409A1 (en) 1997-12-31
DE69717447D1 (de) 2003-01-09
AU720570B2 (en) 2000-06-08
JP2000514044A (ja) 2000-10-24
US6258828B1 (en) 2001-07-10
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
NZ333357A (en) 2000-08-25
CA2258299A1 (en) 1997-12-31
AU3268997A (en) 1998-01-14
EP0910360B1 (en) 2002-11-27
JP2000513351A (ja) 2000-10-10
ATE225178T1 (de) 2002-10-15
NO985917D0 (no) 1998-12-17
JP4162263B2 (ja) 2008-10-08
BR9709942A (pt) 1999-08-10
CN1228703A (zh) 1999-09-15
AU3268897A (en) 1998-01-14
CN1228694A (zh) 1999-09-15
NZ333315A (en) 2000-07-28
WO1997049390A1 (en) 1997-12-31
EP0936915B1 (en) 2002-10-02
NO985916L (no) 1999-01-25
DE69717447T2 (de) 2003-09-11
DE69716104T2 (de) 2003-05-28
JP4359651B2 (ja) 2009-11-04
US6147094A (en) 2000-11-14
GB9613182D0 (en) 1996-08-28
AU720621B2 (en) 2000-06-08
NO985916D0 (no) 1998-12-17
ATE228361T1 (de) 2002-12-15
NO985917L (no) 1999-01-25
CA2259150A1 (en) 1997-12-31
EP0910360A1 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
IL127733A0 (en) Chelating agents and their metal chelates for treating free radical induced conditions
AU1770299A (en) Nitric oxide releasing chelating agents and their therapeutic use
MY135985A (en) Antitumor synergistic composition.
MXPA04004555A (es) Dexrazoxano para tratamiento de cardiotoxicidad inducida por antitumor.
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL129949A (en) Use of minesulide in the preparation of pharmaceutical compositions for treating neurodegenerative conditions
IL131349A0 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
MY136610A (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
WO1998036730A3 (de) Zubereitungen für die behandlung von rosacea
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
CA2294243A1 (en) Novel cyanoaziridines for treating cancer
AU5434899A (en) Cancer treatment
GB2312375B (en) Agents for treatment of cancer
EP0793499A4 (en) METHOD AND MEANS FOR REDUCING TUMOR DEVELOPMENT BY MEANS OF A COMBINATION OF A TAXAN COMPOUND AND A TELLUR AND / OR SELENIUM COMPOUND
WO1998046193A3 (en) Synergistic method for treating a neoplasm
AU6271100A (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
HK1021135A (en) Chelating agents and their metal chelates for treating free radicals induced conditions